Contineum Therapeutics, Inc. (CTNM) stock
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.86+0.08 (+0.82%)
Close on Nov 13, 2026Market cap $370.94MP/E –Yield –
Contineum Therapeutics cash
Cash and short-term investments held at the end of each period.
Contineum Therapeutics's cash was $236.60M at Jun 30, 2026. For fiscal 2025 it was $262.90M, up 28.4% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.90M | +28.4% |
| FY2024 | Dec 31, 2024 | $204.80M | +63.6% |
| FY2023 | Dec 31, 2023 | $125.19M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $236.60M | +34.8% |
| Q1 FY2026 | Mar 31, 2026 | $246.30M | +29.2% |
| Q4 FY2025 | Dec 31, 2025 | $262.90M | +28.4% |
| Q3 FY2025 | Sep 30, 2025 | $182.40M | -14.7% |
| Q2 FY2025 | Jun 30, 2025 | $175.50M | -19.8% |
| Q1 FY2025 | Mar 31, 2025 | $190.70M | +61.7% |
| Q4 FY2024 | Dec 31, 2024 | $204.80M | +63.6% |
| Q3 FY2024 | Sep 30, 2024 | $213.90M | – |
| Q2 FY2024 | Jun 30, 2024 | $218.70M | – |
| Q1 FY2024 | Mar 31, 2024 | $117.90M | – |
| Q4 FY2023 | Dec 31, 2023 | $125.19M | – |
See a number that looks wrong?